Home » Newsletters » BioWorld Science

BioWorld Science

April 5, 2001

View Archived Issues

Renewed focus on oncology products at Transgene

AltaRex reports 2000 update

Clinical data reported for an optimized Theratope vaccine formulation

Pharmagenesis establishes development teams for two cancer treatment drug candidates

Cypress Bioscience and Georgetown collaborate on treatment for fibromyalgia syndrome

FDA supports Vical's Allovectin-7 clinical development program

Apomate begins phase II evaluation for cancer detection

Genelabs presents DNA-binding antifungal agents

Aventis creates new Gencell entity and restructures alliance with Introgen

Herceptin receives Japanese approval for treatment of metastatic breast cancer

Carboxypeptidase A-activated antifolate prodrug identified by Dana-Farber

DuPont identifies small-molecule TACE inhibitors for inflammation, autoimmune diseases

Orphan drug designation granted in Europe for Trisenox

Traditional Chinese medicinal formulation useful for alleviating toxicity of chemotherapy

FDA approves Celltech's once-daily ADHD treatment

New topoisomerase I-interactive fluoroindolocarbazole presented by BMS at AACR meeting

Antisense approaches to diabetes discussed at ACS by Isis

Launch announced for Viadur for advanced prostate cancer

Ark Therapeutics obtains positive results in EG-009 phase I/IIa trial

GSK discusses discovery and SAR for new series of dual PPARgamma/PPARalpha activators

Sch-62373, a dual NK1/NK2 antagonist from a series of 2-phenylpiperazines

New TAP anticancer therapeutic CPI-0004Na: design and synthesis reported this week

Sankyo presents new tachykinin antagonists and potential uses

Novel naturally produced compound is selective against H. pylori

Muscarinic M3-selective antagonists designed at Banyu

Thiophene NPY Y5 receptor ligands useful for eating and other disorders

Meiji Seika reports new series interacting with 5-HT4 receptors

Japanese patent covers preparation and use of beta3-adrenoceptor agonists

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
SERCA inhibitor from Sumitomo shows promise for MSA-C treatment
BioWorld Science
At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, Sumitomo Pharma Co....